Patents by Inventor Malgorzata Donata GONCIARZ

Malgorzata Donata GONCIARZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth differentiation factor 15 agonist compounds and methods of using the same
    Patent number: 11104711
    Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 31, 2021
    Assignee: Eli Lilly and Company
    Inventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
  • GROWTH DIFFERENTIATION FACTOR 15 AGONIST COMPOUNDS AND METHODS OF USING THE SAME
    Publication number: 20190309033
    Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 10, 2019
    Inventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
  • Fibroblast growth factor 21 variant, composition , and uses thereof
    Patent number: 9422353
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 23, 2016
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • FIBROBLAST GROWTH FACTOR 21 VARIANTS
    Publication number: 20150141327
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 21, 2015
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 proteins
    Patent number: 8927492
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: January 6, 2015
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 variants
    Patent number: 8883726
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: November 11, 2014
    Assignee: Eli Lilly and Company
    Inventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Malgorzata Donata Gonciarz, Radmila Micanovic
  • FIBROBLAST GROWTH FACTOR 21 PROTEINS
    Publication number: 20140228282
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Application
    Filed: April 23, 2014
    Publication date: August 14, 2014
    Applicant: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 proteins
    Patent number: 8741841
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 3, 2014
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Homodimeric Proteins
    Publication number: 20140056893
    Abstract: This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 27, 2014
    Applicant: Eli Lilly and Company
    Inventors: Tamer Coskun, Ryan James Darling, Malgorzata Donata Gonciarz, Jorge Alsina-Fernandez
  • FIBROBLAST GROWTH FACTOR 21 PROTEINS
    Publication number: 20130330336
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 12, 2013
    Applicant: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • FIBROBLAST GROWTH FACTOR 21 VARIANTS
    Publication number: 20130324460
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Application
    Filed: August 13, 2013
    Publication date: December 5, 2013
    Applicant: Eli Lilly and Company
    Inventors: Craig Duane DICKINSON, David Albert DRIVER, Ryan James DARLING, Malgorzata Donata GONCIARZ, Radmila MICANOVIC